Gut Microbiome Test Results: Why One Sample Got Six Answers

In 2024 a European expert group did what no consumer can: it took one stool specimen and sent it to six commercial microbiome companies. Three rated the bacterial diversity excellent or good, one judged it unfavorable, and the remaining two said average. A single genus came back at 14.16% and flagged high at one laboratory, then at 8.41% and flagged low at another. The stool never changed. Only the test did.

If you have bought a gut microbiome test hoping for a map of your metabolic health, that result is the first thing to understand. Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, authors of The Angry Gut, lay out the problem on camera in Your Gut Bacteria Breathe Out Through Your Mouth. The deeper layer is below: why a census cannot describe activity, what the reference libraries are missing, which gut markers have real numbers, and where measurement fits into repairing the terrain.

A gut microbiome test scored against a population nobody names

No company in that exercise disclosed the reference cohort behind its labels. High, low, favorable and unfavorable were all relative to a group kept off the report, so no score could ever be proven wrong. Two of the six were sold through medical laboratory websites with no prescription required, which means a clinical-looking envelope said nothing about validation.

The panel judged the reports’ interpretations premature and of limited clinical utility. It proposed separating curiosity kits from regulated diagnostic kits. Know who sat on that panel: 21 experts from 8 countries, 38% academic researchers, 19% from pharma and biotechnology and 9% from the food industry. Not regulators, and not a room without interests.

A deeper flaw sits under every reference group. The fullest catalog of gut genomes found a large reservoir of accessory genes specific to individual human populations, so a score computed against someone else’s cohort may compare you to a different gene pool rather than to a healthier person. A metabolic audit starts from markers that can be checked.

A census of residents is not a record of work

For years I read species lists as if they were diagnoses, treating names on a page when the page was only a head count. Sequencing the same stool for both DNA and RNA shows why that fails. In a cohort of adult men, only 44% of the functional pathways the community commonly carried were actually being transcribed, 81 of 182. At the gene-family level the gap widened: 1,569,171 families in the DNA against 602,896 in the RNA.

The same microbes were the main contributors to both the RNA and the DNA in only about one third of pathways. In the other two thirds, the organism carrying a gene was not the one using it, so a report can name the wrong bug for a function.

The reference library is thin as well. More than 70% of gut species in the fullest catalog have never been grown in a laboratory, and 40% of the protein catalog has no known function. Fermentation output, not a species name, is what feeds the colon lining.

How fast the stool moved changed the score

In fifty-three healthy Belgian women, stool consistency tracked every major microbiome marker. Looser stool ran with lower species richness, and Methanobrevibacter and Akkermansia abundance moved with stool form. Faster transit appeared to favor fast-replicating organisms that outrun the washout, although that pattern was absent in people with a Prevotella enterotype.

So part of a diversity score measures how quickly that sample traveled through the colon on the day it was collected. Two samples taken on days with different stool form are not measuring the same thing, and a change between them is not proof of repair or decline. Meal frequency is its own lever on the terrain.

RNA sits closer to activity, and moves more

If DNA shows capacity and RNA shows activity, why not simply test RNA? Because activity moves. DNA-based taxonomic and functional profiles vary less within one person over time than between people, but RNA profiles proved comparably variable within and between subjects, and metagenomic instability accounted for roughly 74% of that. One sample gives durable information about composition, not about transcription.

Among pathways that were over- or under-transcribed, most kept the same direction at each time point. Still, no RNA-based microbiome assay has been prospectively validated to guide therapy, and part of the reason is design. A clean validation cohort excludes metabolic disease, polypharmacy and anxiety, which removes most of the people who need the answer. Metabolic terrain explains why identical treatments diverge.

Breath reads the work directly, with its own error bars

In the RNA data, methanogenesis was encoded and transcribed solely by Methanobrevibacter, carried some of the highest transcript abundance in the cohort, and stayed rare in the DNA. A rare gene worked hard by a single organism gets averaged away in a stool report and appears plainly in exhaled gas.

Breath testing has accuracy problems of its own. When 139 patients with unexplained gas, bloating and diarrhea had both a duodenal culture and a glucose breath test within one week, the two agreed 65.5% of the time, and the breath test caught only 42% of culture-positive cases. Change the protocol and the disease rate moves: one center’s switch to the consensus method raised positivity from 29.7% to 39.5%, with the added positives coming through methane criteria. Cravings answer to the same fermentation output.

Where measurement meets metabolism

Methane reaches beyond the bowel. In eleven prediabetic adults with obesity who were methane positive, 10 days of neomycin plus rifaximin cleared breath methane in eight. In those eight, LDL, total cholesterol and insulin late in a glucose tolerance test improved. The same study found no change in energy harvest, so the idea that methanogens make you heavier by pulling extra calories from food did not hold, and stool methanogen counts did not fall significantly. No control group and no blinding: a hypothesis with a pulse, not a result. Any antibiotic decision belongs with your physician.

The markers with real numbers are the unglamorous ones. Fecal calprotectin separates inflammatory from functional bowel disease at 85.8% sensitivity and 91.7% specificity, but at a 1% prevalence of inflammatory bowel disease its negative predictive value is 99.8% and its positive predictive value only 9%. It excludes superbly and confirms poorly. A cutoff at or below 50 µg/g ran higher sensitivity than a higher cutoff, 87% against 79%. Fecal elastase-1 at 200 µg/g runs 0.94 sensitivity and 0.69 specificity for pancreatic exocrine insufficiency, but watery stool dilutes it and can drag a result falsely low. Systemic inflammation markers follow the same rule-out logic.

The repair logic follows. Measure activity where you can, exclude inflammation cheaply and match each marker to one question. Census kits are built for repeat purchase; a test that ends the testing is poor business and sound medicine. The full evidence, including the weak spots in the methane trials, sits in the Angry Gut Deep Dive on gut testing.

Frequently asked questions

Are at-home gut microbiome tests accurate?

They reliably produce a report and unreliably produce the same answer. One identical sample sent to six companies in 2024 returned diversity verdicts from excellent to unfavorable, and the same genus was labeled high at one lab and low at another. None disclosed its reference population. Treat a kit as curiosity, not diagnosis, and do not build a treatment plan on it. Longevity medicine should rest on measures that hold up.

What does the diversity score on my stool report mean?

Less than the colored bar suggests. Diversity moves with stool consistency, so a looser sample tends to read lower regardless of health. It is also blind to activity: in adult men, less than half of the pathways the community commonly carried were actually being transcribed. It is a number with no disclosed reference and no treatment attached. The microbiome matters to joints in ways a score cannot capture.

Is RNA microbiome testing better than DNA testing?

RNA sits closer to what the community is actually doing, since far fewer gene families show up as transcripts than appear in DNA. But RNA profiles swing within one person over time nearly as much as they differ between people, so one sample is a snapshot, not a baseline. Repeated measures help, and no RNA assay has yet been validated to guide treatment. When treatment still fails, the next suspect may be the environment.

Can methane on a breath test affect blood sugar?

Possibly. In a small single-arm study of eleven prediabetic adults with obesity who were methane positive, those whose breath methane cleared after antibiotics showed improvements in cholesterol and in insulin during a glucose tolerance test. There was no control group, and energy harvest from food did not change. It is a lead worth measuring in the right patient, not a reason to take antibiotics. Continuous glucose data adds context between lab draws.

Which gut tests actually have good evidence?

Fecal calprotectin is the strongest rule-out for inflammatory bowel disease, with a negative predictive value of 99.8% at low prevalence. Fecal elastase-1 screens for pancreatic insufficiency but reads falsely low in watery stool. A breath test measuring hydrogen, methane and carbon dioxide on the consensus protocol reads fermentation activity. None of them is a microbiome score, and each answers one question. A clean result is not always the end of the story.

Sources

1. Rodriguez, J., Cordaillat-Simmons, M., Badalato, N., Berger, B., Breton, H., de Lahondès, R., Deschasaux-Tanguy, M., Desvignes, C., D’Humières, C., Kampshoff, S., Lavelle, A., Metwaly, A., Quijada, N. M., Seegers, J. F. M. L., Udocor, A., Zwart, H., Maguin, E., Doré, J., & Druart, C. (2024). Microbiome testing in Europe: Navigating analytical, ethical and regulatory challenges. Microbiome, 12(1), 258. https://doi.org/10.1186/s40168-024-01991-x
2. Abu-Ali, G. S., Mehta, R. S., Lloyd-Price, J., Mallick, H., Branck, T., Ivey, K. L., Drew, D. A., DuLong, C., Rimm, E., Izard, J., Chan, A. T., & Huttenhower, C. (2018). Metatranscriptome of human faecal microbial communities in a cohort of adult men. Nature Microbiology, 3(3), 356-366. https://doi.org/10.1038/s41564-017-0084-4
3. Almeida, A., Nayfach, S., Boland, M., Strozzi, F., Beracochea, M., Shi, Z. J., Pollard, K. S., Sakharova, E., Parks, D. H., Hugenholtz, P., Segata, N., Kyrpides, N. C., & Finn, R. D. (2021). A unified catalog of 204,938 reference genomes from the human gut microbiome. Nature Biotechnology, 39(1), 105-114. https://doi.org/10.1038/s41587-020-0603-3
4. Vandeputte, D., Falony, G., Vieira-Silva, S., Tito, R. Y., Joossens, M., & Raes, J. (2016). Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut, 65(1), 57-62. https://doi.org/10.1136/gutjnl-2015-309618
5. Mehta, R. S., Abu-Ali, G. S., Drew, D. A., Lloyd-Price, J., Subramanian, A., Lochhead, P., Joshi, A. D., Ivey, K. L., Khalili, H., Brown, G. T., DuLong, C., Song, M., Nguyen, L. H., Mallick, H., Rimm, E. B., Izard, J., Huttenhower, C., & Chan, A. T. (2018). Stability of the human faecal microbiome in a cohort of adult men. Nature Microbiology, 3(3), 347-355. https://doi.org/10.1038/s41564-017-0096-0
6. Erdogan, A., Rao, S. S. C., Gulley, D., Jacobs, C., Lee, Y. Y., & Badger, C. (2015). Small intestinal bacterial overgrowth: Duodenal aspiration vs glucose breath test. Neurogastroenterology and Motility, 27(4), 481-9. https://doi.org/10.1111/nmo.12516
7. Baker, J. R., Chey, W. D., Watts, L., Armstrong, M., Collins, K., Lee, A. A., Dupati, A., Menees, S., Saad, R. J., Harer, K., & Hasler, W. L. (2021). How the North American Consensus protocol affects the performance of glucose breath testing for bacterial overgrowth versus a traditional method. The American Journal of Gastroenterology, 116(4), 780-787. https://doi.org/10.14309/ajg.0000000000001110
8. Mathur, R., Chua, K. S., Mamelak, M., Morales, W., Barlow, G. M., Thomas, R., Stefanovski, D., Weitsman, S., Marsh, Z., Bergman, R. N., & Pimentel, M. (2016). Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity. Obesity (Silver Spring), 24(3), 576-82. https://doi.org/10.1002/oby.21385
9. Dajti, E., Frazzoni, L., Iascone, V., Secco, M., Vestito, A., Fuccio, L., Eusebi, L. H., Fusaroli, P., Rizzello, F., Calabrese, C., Gionchetti, P., Bazzoli, F., & Zagari, R. M. (2023). Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults. Alimentary Pharmacology & Therapeutics, 58(11-12), 1120-1131. https://doi.org/10.1111/apt.17754
10. de la Iglesia, D., Agudo-Castillo, B., Galego-Fernández, M., Rama-Fernández, A., & Domínguez-Muñoz, J. E. (2025). Diagnostic accuracy of fecal elastase-1 test for pancreatic exocrine insufficiency: A systematic review and meta-analysis. United European Gastroenterology Journal, 13(8), 1571-1582. https://doi.org/10.1002/ueg2.70061

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 25 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.